TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone in Threatened Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women attending the emergency room of the study sites with the following characteristics:~* Able and willing to sign the Subject Informed Consent Form and adhere to the study visit schedule;~* Age: 18-37 years;~* BMI: 18-28 kg/m2;~* Symptoms of threatened abortion (vaginal bleeding , with or without pelvic pain);~* Ultrasound proof of viable singleton intrauterine pregnancy (positive foetal heart beat);~* Gestation week ≥6 weeks (5 w +1d) and \<12 weeks (11 w + 1d) according to ultrasound dating (CRL);~* Closed uterine cervix;~* At the first case of threatened abortion in the current pregnancy.~Exclusion Criteria:~* Pregnancy obtained via ART treatment;~* Subchorionic haematoma with \>50% placental detachment;~* History of recurrent miscarriage;~* Severe uterine malformations;~* Known hypersensitivity to study medication;~* Neoplasias (known or suspected breast or genital tract cancer);~* Severe impairment of hepatic or renal function;~* Use of concomitant medications that might interfere with study evaluations (other hormonal treatment or drugs affecting uterine contractility);~* Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events;~* Porphyria;~* A history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy;~* Antiphospholipid syndrome;~* Diabetes mellitus;~* Known thyroid diseases or autoimmune conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: EXPERIMENTAL): 25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
- Placebo (Type: PLACEBO_COMPARATOR): placebo will be administered twice à day until the 12th week of gestation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion~* Ambulatory, male or female patients aged ≥25 - ≤65 years~* Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4~* Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13~Key Exclusion Criteria:~* Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years~* Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 halflives of the oligonucleotide, whichever is longer~* Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy~* Inability to undergo brain MRI~* Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- WVE-120102 (2 mg) or placebo (Type: EXPERIMENTAL): None
- WVE-120102 (4 mg) or placebo (Type: EXPERIMENTAL): None
- WVE-120102 (8 mg) or placebo (Type: EXPERIMENTAL): None
- WVE-120102 (16 mg) or placebo (Type: EXPERIMENTAL): None
- WVE-120102 (32 mg ) or placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiosurgery (SRS) for Spine Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Age greater than or equal to 18 years old.~* Prior histologically-proven, non-hematogenous malignancy (Specific exclusions are multiple myeloma and lymphoma).~* Radiographic evidence of one or two non-contiguous spinal metastases amenable to SRS.~* Metastatic disease must be symptomatic (causing either pain or neurologic symptoms).~* Maximum tumor size less than or equal to 5 cm.~* Zubrod performance status of less than or equal to 3.~* Life expectancy of greater than or equal to 3 months.~* Women/Men of childbearing potential must use effective contraception.~Exclusion Criteria:~* No prior radiation delivered to the involved area~* No evidence of spinal instability requiring urgent surgical intervention.~* No evidence of spinal cord compression requiring emergent surgical or radiotherapeutic intervention.~* No plans for concomitant antineoplastic therapy (including standard fractionated RT, chemotherapy, biologic, vaccine therapy, or surgery) while on this protocol except at disease progression.Concomitant is defined as within 3 days before or after radiosurgery.~* No pregnant or lactating women.~* No active systemic infection.~* No evidence of myelopathy or cauda equina syndrome on clinical evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
- 2 (Type: ACTIVE_COMPARATOR): High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Loss of more than 10% of maximum weight or failure to gain weight for 2 months.~* Having cough with wheeze for 4 weeks or more.~* History of household contact with a probable or confirmed tuberculosis case in the past 6 months.~* Pyrexia of unknown origin.~* Painless swelling in a group of cervical lymph nodes.~* Children who were diagnosed with TB in the past 5 years and have received anti-tuberculosis therapy for a period less than 4 weeks.~Exclusion Criteria:~-Children who have been treated with anti-tuberculosis therapy exceeding 4 weeks in the past one year will not be eligible for entry into the study

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Multivitamins (Type: EXPERIMENTAL): Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-small cell carcinoma of the lung~* Initially unresectable non-metastatic stage III disease~* Availability for participating in the detailed follow-up of the protocol~* Presence of an evaluable or measurable lesion~* Written informed consent~* No functional or anatomical contraindication to chest irradiation~Exclusion Criteria:~* Prior treatment with chemotherapy, radiotherapy or surgery~* Performance status \< 60 on the Karnofsky scale~* History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)~* Neutrophils \< 2,000/mm³~* Platelet cells \< 100,000/mm3~* Serum bilirubin \> 1.5 mg/100 ml~* Hepatic disease contra-indicating the administration of docetaxel and/or GOT or GPT ≥ 2.5x the normal value and/or alkaline phosphatase ≥ 5x the normal value~* Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 60 ml/min~* Recent myocardial infarction (less than 3 months prior to date of diagnosis) or uncontrolled angina pectoris~* Congestive cardiac failure or cardiac arrhythmia requiring medical treatment~* Uncontrolled infectious disease~* Symptomatic polyneuropathy~* Auditive impairment contra-indicating cisplatin administration~* Serious medical or psychological factors which may prevent adherence to the treatment schedule~* Malignant pleural or pericardial effusion~* Homolateral supraclavicular lymph node excepting upper lobe lesion~* Heterolateral supraclavicular lymph node~* Known hypersensitivity to docetaxel or cisplatin~* Pregnancy or for pre-menopausal patient, incapacity to use adequate contraceptive method

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
- B (Type: EXPERIMENTAL): Three courses of induction chemotherapy followed by consolidation chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index ≥40 kg/m2 at time of delivery~* Delivered by cesarean delivery~* 18 years or later~Exclusion Criteria:~* Chorioamnionitis~* Silver allergy~* Inability to follow up

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Negative pressure wound therapy (NPWT) (Type: EXPERIMENTAL): Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
- Standard dressing (Type: PLACEBO_COMPARATOR): Standard dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 85 years~* No contraindication to electrical stimulation~* Oropharyngeal dysphagia from 8 weeks diagnosed by videofluorosocpy with penetration aspiration scale \> 3 or a residue ≥ 50%~* Due to an hemispheric stroke~* Patients able to understand the videofluroscopy and questionnaires~* For women in age of procreation, to have a contraception, a pregnacy test will be done if not~* Able to swallow (a nasogastric tube is not a contraindication to participate)~Exclusion Criteria:~* Pregnancy or breast feeding~* Psychiatric illnes~* Swallowing disorders before the stroke~* Contraindication to electrical stimulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- active stimulation (Type: EXPERIMENTAL): sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks
- fake stimulation (Type: PLACEBO_COMPARATOR): Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old, diagnosed C diff colitis requiring surgical intervention~Exclusion Criteria:~* CHF previously diagnosed, pregnancy, prisoners/ incarcerated, previous administration of IVIG within 30-days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bezlotoxumab (Type: EXPERIMENTAL): Patients receiving Bezlotoxumab post-operatively.
- Normal Saline (Type: PLACEBO_COMPARATOR): Patients receiving normal saline as a placebo post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inferior Turbinate Reduction in Pediatric Population Failing Surgery for Sleep Disordered Breathing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients that underwent tonsillectomy and adenoidectomy for obstructive sleep apnea, sleep related breathing disorder, snoring, disturbed sleeping, open mouth breathing, and upper airway resistance syndrome with persistent symptomatology.~2. Enlarged inferior turbinates with nasal obstruction (\>25%).~3. Age 0-18 years.~4. Lack of improvement of obstructive sleep apnea symptoms after maximal medical treatment with intranasal steroids in patients with symptoms of ARS and H2 blocker medication in patients with symptoms of LPR.~Exclusion Criteria:~1. Previous adenotonsillar surgery or placement of tympanostomy tubes for recurrent otitis media, tonsillitis, or sinusitis.~2. Patients with BMI \> 97% for age and sex.~3. Patients with craniofacial abnormalities.~4. Patients with previous airway issues, anatomic variance from normal, mallampati class III or IV, septal deviation, choanal stenosis, and nasal stenosis.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): No inferior turbinate surgery.
- Intervention (Type: OTHER): Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 and \<75 years of age that meet the American College of Rheumatology (ACR) criteria for RA.~* Patients with active RA defined as:~  1. ≥3 tender joints and ≥3 swollen joints, or~ 2. DAS 28 score \>3.1~* Patients who are discontinuing treatment with either infliximab or etanercept due to:~  1. Lack of efficacy, or~ 2. Incomplete response.~* Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab~* Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.~Exclusion Criteria:~The following patients will not be included in the study:~* Patients who have active infections.~* Patients with latent TB. For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray.~* Patients participating into another study or clinical trial~* Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Non responders to other anti-TNF (Type: None): Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization~* Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment~* Completely studies~Exclusion Criteria:~Complications~* Tractional Detachment~* Endophthalmitis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertrophic burn scar present on trunk or abdomen~Exclusion Criteria:~* Initial burn injury less than 1 year old~* History of chemical or electrical burn~* Genetic or acquired conditions that severely affect systemic wound healing or collagen formation (vasculitis, diabetes, Ehlers-Danlos syndrome, radiation therapy to the scar site or use of immunosuppressive medications within the last year, active cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- PRP injection right half (Type: EXPERIMENTAL): The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the control half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL normal saline into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment.
- PRP injection left half (Type: EXPERIMENTAL): The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the experimental half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL PRP into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Quality of Life Study in Patients With Migraines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years of age or older~* Have the diagnosis of migraine~* Have had no change in migraine medication(s) 30 days prior to study~* Achieve a satisfactory score on the Wide Range Achievement Test 3 (WRAT3) test at the screening visit~* Capable of completing self-reporting questionnaires~* Willing and able to provide written informed consent and comply with the study protocol~Exclusion Criteria:~* Presence of a clinically significant comorbidity of an unstable or progressive nature~* Presence of major depression~* Participation in an investigational drug study within the past 30 days~* Inability to communicate well with site study personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval